← Back to Search

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

Phase 1
Waitlist Available
Led By David Russell
Research Sponsored by Invicro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Creation of a database of brain amyloid deposition by region using PET signal-to-noise ratio, SUVr .
Secondary study objectives
Creation of a database of blood P-tau217 and other blood biomarkers.

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]FlorbetapirExperimental Treatment1 Intervention
Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, \[18F\]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Florbetapir (18F)
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

InvicroLead Sponsor
18 Previous Clinical Trials
274 Total Patients Enrolled
David RussellPrincipal InvestigatorInvicro
~47 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top